Kolltan, which is backed by Purdue Pharma and Gilead Sciences, will use the proceeds to advance its candidates through early-stage clinical trials.
US-based biopharmaceutical company Kolltan Pharmaceuticals filed for an initial public offering on Friday that could raise up to $86.25m.
Founded in 2007, Kolltan is developing antibody-based treatments for cancer and other diseases, and will use the proceeds from the IPO to advance its product candidates through early clinical trials.
The company has raised $125m in equity funding from pharmaceutical company Purdue Pharma, as well as KlP Enterprises, Deerfield Capital Management, HBM Healthcare Investments, Osage University Partners, Celtic Therapeutics Holdings and…
